clinical trial · NCT05632354
GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD)
Pfizer·phase3·terminated·n = 47
Sickle Cell DiseaseOsivelotor
brief summary
An Open-label Extension Study of GBT021601 in Participants with Sickle Cell Disease
started
Jan 5, 2023
primary completion
Feb 13, 2025
completion
Feb 13, 2025
last updated
Mar 19, 2026
detailed description
An Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of GBT021601 Administered to Participants with Sickle Cell Disease Who Have Participated in a GBT021601 Clinical Trial
official title
An Open-label Extension Study to Evaluate the Long-term Safety of GBT021601 Administered to Participants With Sickle Cell Disease Who Have Participated in a GBT021601 Clinical Trial
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol